FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
However, the agency says all seven gadolinium-based contrast agents used in MRI and MRA procedures present a risk of nephrogenic systemic fibrosis.